Chengdu Olymvax Biopharmaceuticals Inc. A
Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b. It also provides Hib conjugate vaccine and AC conjugate vaccine; and group A and C meningococcal polysaccharide conjugate vaccine. The company was fou… Read more
Chengdu Olymvax Biopharmaceuticals Inc. A (688319) - Total Assets
Latest total assets as of September 2025: CN¥1.94 Billion CNY
Based on the latest financial reports, Chengdu Olymvax Biopharmaceuticals Inc. A (688319) holds total assets worth CN¥1.94 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Chengdu Olymvax Biopharmaceuticals Inc. A - Total Assets Trend (2013–2024)
This chart illustrates how Chengdu Olymvax Biopharmaceuticals Inc. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Chengdu Olymvax Biopharmaceuticals Inc. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Chengdu Olymvax Biopharmaceuticals Inc. A's total assets of CN¥1.94 Billion consist of 50.3% current assets and 49.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 12.4% |
| Accounts Receivable | CN¥571.35 Million | 31.6% |
| Inventory | CN¥85.68 Million | 4.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥299.22 Million | 16.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Chengdu Olymvax Biopharmaceuticals Inc. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chengdu Olymvax Biopharmaceuticals Inc. A's current assets represent 50.3% of total assets in 2024, an increase from 20.9% in 2013.
- Cash Position: Cash and equivalents constituted 12.4% of total assets in 2024, up from 9.7% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 5.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 31.6% of total assets.
Chengdu Olymvax Biopharmaceuticals Inc. A Competitors by Total Assets
Key competitors of Chengdu Olymvax Biopharmaceuticals Inc. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Chengdu Olymvax Biopharmaceuticals Inc. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Chengdu Olymvax Biopharmaceuticals Inc. A generates 0.33x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Chengdu Olymvax Biopharmaceuticals Inc. A generates $ 1.15 in net profit.
Chengdu Olymvax Biopharmaceuticals Inc. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.52 | 1.86 | 1.51 |
| Quick Ratio | 1.42 | 1.67 | 1.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥331.83 Million | CN¥ 415.86 Million | CN¥ 122.93 Million |
Chengdu Olymvax Biopharmaceuticals Inc. A - Advanced Valuation Insights
This section examines the relationship between Chengdu Olymvax Biopharmaceuticals Inc. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.85 |
| Latest Market Cap to Assets Ratio | 0.59 |
| Asset Growth Rate (YoY) | 12.1% |
| Total Assets | CN¥1.81 Billion |
| Market Capitalization | $1.06 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Chengdu Olymvax Biopharmaceuticals Inc. A's assets below their book value (0.59 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Chengdu Olymvax Biopharmaceuticals Inc. A's assets grew by 12.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Chengdu Olymvax Biopharmaceuticals Inc. A (2013–2024)
The table below shows the annual total assets of Chengdu Olymvax Biopharmaceuticals Inc. A from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.81 Billion | +12.06% |
| 2023-12-31 | CN¥1.61 Billion | +9.04% |
| 2022-12-31 | CN¥1.48 Billion | +22.03% |
| 2021-12-31 | CN¥1.21 Billion | +88.99% |
| 2020-12-31 | CN¥641.26 Million | +31.39% |
| 2019-12-31 | CN¥488.04 Million | +72.84% |
| 2018-12-31 | CN¥282.37 Million | +4.23% |
| 2017-12-31 | CN¥270.90 Million | +32.90% |
| 2016-12-31 | CN¥203.83 Million | -23.20% |
| 2015-12-31 | CN¥265.41 Million | +24.19% |
| 2014-12-31 | CN¥213.72 Million | -6.66% |
| 2013-12-31 | CN¥228.97 Million | -- |